- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Walgreens launches high-impact push in support of World AIDS Day campaign
- Walgreens allies with HHS to launch free flu shot outreach to disadvantaged
- Gilead resubmits HIV drug application to FDA
- FDA approves Merck's Gardasil for prevention of anal cancer
FOSTER CITY, Calif. — The Food and Drug Administration has approved a new single-pill treatment for HIV made by Gilead Sciences and Johnson & Johnson, Gilead said.
Gilead announced the approval of Complera (emtricitabine, rilpivirine, tenofovir disoproxil fumarate). The drug combines Gilead's Truvada with J&J's Edurant.
"In the 30 years since the first AIDS cases were reported, we've made incredible strides in the treatment of this disease," said Tony Mills, director of medical research at Anthony Mills MD Inc. and investigator in Complera studies. "The concept of a single-tablet regimen has become a goal in HIV drug development, and the standard of care in medical practice in the United States."